Meanwhile, the prognostic genes in this study (such as the high expression of SLC7A11 and low expression of CBS) can be used as biomarkers for the prognostic stratification and treatment sensitivity prediction of HCC patients, facilitating the formulation of personalized treatment plans. This evidence concerns the gene SLC7A11 and hepatocellular carcinoma.